Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL1724146 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| Tetrahydrofuran SCHEMBL11026489 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| Cyclopropane SCHEMBL3744694 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| SCHEMBL2846103 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| SCHEMBL5386353 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| SCHEMBL4788259 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| SCHEMBL2848269 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| SCHEMBL2845030 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| SCHEMBL10713952 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A | |
| SCHEMBL4456224 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TSHRTTRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637662-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-01-28 | — | — | US | claimed |
| EP-2496682-A1 | DELIVERY PARTICLE | The Procter & Gamble Company (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2013207-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2012-04-25 | — | — | EP | disclosed |
| EP-2427509-A1 | POLYMER COMPOSITION | Contamac Limited (GB) | 2012-03-14 | — | — | EP | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-20120053313-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2422183-A2 | OXIDATION STATE SENSORS AND METHODS FOR TRANSITION METAL ALLOYS | Rolls-Royce PLC (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20120040467-A1 | OXIDATION STATE SENSORS AND METHODS FOR TRANSITION METAL ALLOYS | ROLLS-ROYCE PLC | 2012-02-16 | — | — | US | disclosed |
| EP-1330456-B8 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20120021223-A1 | CHEMICAL AGENTS CAPABLE OF FORMING COVALENT 3-D NETWORKS | OXFORD ADVANCED SURFACES LTD. (GB) | 2012-01-26 | — | — | US | disclosed |
| EP-1575955-B1 | PYRROLOBENZODIAZEPINES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| EP-1831184-B1 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | WELLCOME TRUST LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-20110015409-A1 | SYNTHESIS OF CYCLIC CARBONATES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2011-01-20 | — | — | US | disclosed |
| EP-2274282-A1 | COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS | Medical Research Council (GB) | 2011-01-19 | — | — | EP | disclosed |
| EP-2270010-A1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | Spirogen Limited (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20050154031-A1 | 5-Ht2b receptor antagonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-6121311-A | Method for treating cocainism | JAPAN TOBACCO INC. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0996414-A1 | PERFUMED ONE AND TWO PHASE COMPOSITIONS FOR REDUCING BODY ODOR AND METHODS OF USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1998056342-A1 | PERFUMED ONE AND TWO PHASE COMPOSITIONS FOR REDUCING BODY ODOR AND METHODS OF USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053313-A1 | POLYMER COMPOSITION | UACA, CRYAA, CRYZ | ALDH1A1 3560/4885TSHR 4518/4885TTR 1271/4885 |
| US-20050154031-A1 | 5-Ht2b receptor antagonists | HTR2B, HTR3B, HTR7 | ALDH1A1 2010/4885TSHR 71/4885TTR 3144/4885 |
| US-20110015409-A1 | SYNTHESIS OF CYCLIC CARBONATES | NR3C2, NR2C2, NR3C1 | ALDH1A1 3200/4885TSHR 624/4885TTR 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.